BFH772 (VEGFR2 inhibitor): Technical Application and Protocol Guide

What This Product Solves

BFH772 (CAS 890128-81-1) addresses the need for a highly selective VEGFR2 kinase inhibitor within angiogenesis and tumor vascularization research workflows. By offering potent inhibition (IC50: 3 nM) of VEGFR2 over closely related family members (FLK-1, FLT-1, FLT-4) and other kinases such as B-RAF, RET, and TIE-2, BFH772 enables researchers to dissect VEGFR2-mediated signaling pathways with minimal off-target effects. This selectivity is especially critical in studies where precise modulation of the VEGFR2 signaling axis is required to evaluate the molecular mechanisms of angiogenesis or tumor growth suppression. BFH772 is not suited for protocols requiring broad kinase inhibition or water-soluble reagents, but is ideal for advanced tumor angiogenesis assays and other models where VEGFR2-driven events are the central focus. For further reference, the Practical Guidance for Angiogenesis Research article provides workflow context for comparable use cases.

Protocol Parameters

• Assay: In vitro kinase inhibition
  Value: IC50 = 3 nM
  Applicability: Determining the minimum effective concentration for VEGFR2 pathway inhibition in cell-based assays.
  Rationale: Enables dose-response studies requiring high specificity against VEGFR2.
  Source type: product information
• Assay: Compound dissolution
  Value: Soluble at ≥53.4 mg/mL in DMSO, ≥15.33 mg/mL in ethanol; insoluble in water
  Applicability: Preparation of stock solutions for in vitro and in vivo protocols.
  Rationale: Ensures compound integrity and homogeneous application within organic solvent-compatible workflows.
  Source type: product information
• Assay: Storage and handling
  Value: Store at -20°C; avoid long-term storage of solutions
  Applicability: Short-term and batch-wise experimental design.
  Rationale: Maintains compound stability and prevents degradation that could compromise experimental results.
  Source type: product information
• Assay: Selectivity window
  Value: ~500-fold selectivity over FLK-1, FLT-1, FLT-4; ~40-fold over B-RAF, RET, TIE-2
  Applicability: Designs requiring specific VEGFR2 inhibition with minimal interference from other kinases.
  Rationale: Reduces confounding effects in pathway-specific studies.
  Source type: product information

Workflow Setup and QC Checklist

To ensure reproducibility and robust data generation with BFH772, adhere to the following workflow and quality control best practices:

• Stock Preparation: Dissolve BFH772 in DMSO or ethanol at concentrations not exceeding the documented solubility limits. Avoid water as a solvent due to insolubility; filter-sterilize stocks if required for cell-based work.
• Aliquoting: Prepare single-use aliquots to prevent repeated freeze-thaw cycles, which can degrade compound potency.
• Experimental Controls: Always include vehicle (DMSO or ethanol) controls to distinguish specific effects of the VEGFR2 inhibitor from solvent artifacts.
• Purity Confirmation: Verify that each batch is accompanied by a certificate of analysis confirming >96% purity as per APExBIO specifications.
• Storage: Maintain solid compound at -20°C. Use freshly prepared solutions and avoid storing stocks in solution long-term.
• Documentation: Retain safety data sheets and batch-specific QC certificates for compliance and troubleshooting purposes.

For detailed protocol adaptation in angiogenesis models, review the Technical Use, Protocols, and QC Guide, which covers BFH772 application parameters and quality control in practical research settings.

Common Failure Modes and Fixes

• Incomplete Dissolution: If crystals are visible or solutions appear cloudy, increase DMSO or ethanol proportion, gently vortex, and apply mild heating (≤37°C) if necessary. Never attempt to dissolve BFH772 in aqueous buffers directly.
• Loss of Activity: Decreased efficacy may result from multiple freeze-thaw cycles or extended solution storage. Always use fresh aliquots and limit exposure to room temperature.
• Off-target Effects: Higher concentrations may reduce selectivity. Use minimal effective concentrations established from dose-response pilot experiments to preserve specificity for VEGFR2.
• Batch Variability: Discrepancies in experimental outcomes can often be traced to differences in compound purity or preparation; always confirm with batch-specific QC data.

Scope and Limitations

BFH772 is suitable for research applications requiring selective inhibition of the VEGFR2 signaling pathway, such as investigating mechanisms of angiogenesis or tumor progression in preclinical models. Its utility is limited in workflows that demand water-soluble reagents, broad-spectrum kinase inhibition, or extended solution storage. Researchers should avoid applying BFH772 in protocols where its organic solvent requirements or selectivity window may confound interpretation, such as multiplexed kinase assays or water-based high-throughput screens. Methodological boundaries and use-cases are detailed in the Technical Guidance for Angiogenesis Assays, which outlines handling and solubility restrictions for this compound.

Conclusion

BFH772 (VEGFR2 inhibitor) offers robust selectivity and potency for targeted inhibition of VEGFR2-driven angiogenic processes in research settings. By following solubility, storage, and protocol parameters as outlined in the product information, researchers can maximize data integrity and reproducibility. The compound's defined selectivity and handling requirements make it particularly well-suited for focused mechanistic studies in tumor angiogenesis, rather than for broad or aqueous-based screening applications.